Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
25399731
Public Release Type:
Journal
Publication Year: 2014
Affiliation: From the Mayo Clinic College of Medicine, Rochester, MN (V.E.T., M.C.H., P.C.H.); University of Pittsburgh School of Medicine, Pittsburgh (K.Z.A., C.G.M.); Emory University School of Medicine, Atlanta (A.B.C., F.F.R.-O.); University of Colorado Health Sciences Center, Denver (R.W.S., G.B.); Cleveland Clinic, Cleveland (W.E.B.); Beth Israel Deaconess Medical Center (T.I.S., P.G.C.) and Tufts Medical Center (D.C.M., R.D.P.) - both in Boston; Kansas University Medical Center, Kansas City (F.T.W., J.J.G.) and the National Institutes of Health, Bethesda, MD (M.F.F.).
DOI:
https://doi.org/10.1056/NEJMoa1402686
Authors:
Glockner J,
Rahbari-Oskoui FF,
Torres VE,
Abebe KZ,
Chapman AB,
Schrier RW,
Braun WE,
Steinman TI,
Winklhofer FT,
Brosnahan G,
Czarnecki PG,
Hogan MC,
Miskulin DC,
Grantham JJ,
Harris PC,
Flessner MF,
Moore CG,
Perrone RD,
HALT-PKD Trial Investigators,
Steinman T,
Wei J,
Czarnecki P,
Pedrosa I,
Braun W,
Nurko S,
Remer E,
Chapman A,
Martin D,
Rahbari-Oskoui F,
Mittal P,
Torres V,
Hogan MC,
El-Zoghby Z,
Harris P,
King B Jr,
Perrone R,
Halin N,
Miskulin D,
Schrier R,
Brosnahan G,
Gitomer B,
Kelleher C,
Masoumi A,
Patel N,
Winklhofer F,
Grantham J,
Yu A,
Wang C,
Wetzel L,
Moore CG,
Bost JE,
Bae K,
Abebe KZ,
Miller J,
Thompson PA,
Briggs J,
Flessner M,
Meyers CM,
Star R,
Shayman J,
Henrich W,
Greene T,
Leonard M,
McCullough P,
Moe S,
Rocco M,
Wendler D
Hypertension develops early in patients with autosomal dominant polycystic kidney disease (ADPKD) and is associated with disease progression. The renin-angiotensin-aldosterone system (RAAS) is implicated in the pathogenesis of hypertension in patients with ADPKD. Dual blockade of the RAAS may circumvent compensatory mechanisms that limit the efficacy of monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB).
